References
- Regulation (EC) No 1394/2007 of the European Parliament and of the Council of Nov 13, 2007, on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. November 2017 [cited 2019 Dec 08] governs ATMP development for human use. Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02007R1394-20120702
- Halioua-Haubold CL, Peyer JG, Smith JA, et al. Regulatory considerations for gene therapy products in the US, EU, and Japan. Yale J Biol Med. 2017;90:683–693.
- European Medicines Agency. Reflection paper on the classification of advanced therapy medicinal products. May 2015. [cited 2019 Feb 11]. Available from: www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-classification-advanced-therapy-medicinal-products_en-0.pdf
- US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for Human Somatic Cell Therapy and Gene Therapy. March 1998. [cited 2020 Feb 11]. Available from: www.fda.gov/media/72402/download
- US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Regulatory. Considerations for human cells, tissues, and cellular and tissue-based products: Minimal manipulation and homologous use. Guidance for Industry and Food and Drug Administration Staff. December 2017. [cited 2020 Feb 11]. Available from: www.fda.gov/media//124138/download
- de Wilde S, Guchelaar HJ, Zandvliet ML, et al. Clinical development of gene-and cell-based therapies: overview of the European landscape. Mol Ther Methods Clin Dev. 2016;3:16073.
- Pearce KF, Hildebrandt M, Greinix H, et al. Regulation of advanced therapy medicinal products in Europe and the role of academia. Cytotherapy. 2014;16:289–297.
- Seimetz D. The key to successful drug approval: an effective regulatory strategy. Life Science Venturing. 2017. DOI:10.1007/978-3-658-06382-5_7.
- European Medicines Agency. Human Regulatory Guidelines relevant for advanced therapy medicinal products. [cited 2019 Dec 08]. Available from: www.ema.europa.eu/en/human-regulatory/research-development/advanced-therapies/guidelines-relevant-advanced-therapy-medicinal-products
- Detela G, Lodge A. EU Regulatory Pathways for ATMPs: standard, accelerated, and adaptive pathways to marketing authorization. Mol Ther Methods Clin Dev. 2019;29(13):205–232.
- Seimetz D, Heller K, Richter J. Approval of first CAR-Ts: have we solved all hurdles for ATMPs? Cell Med. 2019;11:1–16.
- Seoane-Vazquez E, Shukla V, Rodriguez-Monguio R. Innovation and competition in advanced therapy medicinal products. EMBO Mol Med. 2019;11:e9992. [ PII].
- EMA. Orphan incentives. [cited 2019 Dec 08]. Available from: www.ema.europa.eu/en/human-regulatory/research-development/orphan-designation/orphan-incentives
- US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Considerations for the design of early-phase clinical trials of cellular and gene therapy products. Guidance for Industry. June 2015. [cited 2020 Feb 11]. Available from: www.fda.gov/media/106369/download
- EMA. Guideline on safety and efficacy follow-up and risk management of advanced therapy medicinal products. Draft. January 2018. [cited 2020 Feb 11]. Available from: www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-safety-efficacy-follow-risk-management-advanced-therapy-medicinal-products-revision_en.pdf
- US Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Guidance for Industry. Long term follow-up after administration of human gene therapy products. January 2020 [cited 2020 Feb 11]. Available from: www.fda.gov/media/113768/download
- Committee for medicinal products for human use (CHMP). Guideline on follow-up of patients administered with gene therapy medicinal products. May 2010. [cited 2020 Feb 11]. Available from: www.ema.europa.eu/en/documents/scientific-guideline/guideline-follow-patients-administered-gene-therapy-medicinal-products_en.pdf
- Thompson AA, Walters MC, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent β-thalassemia. N Engl J Med. 2018;378:1479–1493.
- Zynteglo™. EPAR last updated on 14/11/2019 [cited 2019 Dec 08]. Available from: www.ema.europa.eu/en/medicines/human/EPAR/zynteglo
- Summary of risk management plan for Zynteglo (an autologous CD34+ cell-enriched population that contains hematopoietic stem cells transduced with a lentiviral vector encoding the βA-T87Q-globin gene). [cited 2019 Dec 08]. Available from: www.ema.europa.eu/en/documents/rmp-summary/zynteglo-epar-risk-management-plan-summary_en.pdf
- FDA. Kymriah (tisagenlecleucel). March 2018 [cited 2019 Dec 08]. Available from: www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel
- Miliotou AN, Papadopoulou LC. CAR T-cell therapy: A new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018;19:5–18.
- Feins S, Kong W, Williams EF, et al. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3–S9.
- Sermer D, Brentjens R. CAR T-cell therapy: full speed ahead. Hematol Oncol. 2019;37(Suppl 1):95–100.
- Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations, and management. Blood Rev. 2019;34:45–55.
- Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16:372–385.
- Barman A, Deb B, Chakraborty S. A glance at genome editing with CRISPR-Cas9 technology. Curr Genet. 2019 Nov 5. DOI:10.1007/s00294-019-01040-3.
- Schacker M, Seimetz D. From fiction to science: clinical potentials and regulatory considerations of gene editing. Clin Transl Med. 2019;8:27.
- Cathomen T, Schüle S, Schüßler-Lenz M, et al. The human genome editing race: loosening regulatory standards for commercial advantage? Trends Biotechnol. 2019;37:120–123.
- CRISPR. Therapeutics and Vertex announce favorable safety and efficacy data from the first two patients treated with investigational CRISPR/Cas9 gene-editing therapy CTX001® for severe hemoglobinopathies. [cited 2019 Dec 06]. Available from: https://crisprtx.gcs-web.com/node/9146/pdf
- Tiburcy M, Hudson JE, Balfanz P, et al. Defined engineered human myocardium with advanced maturation for applications in heart failure modeling and repair. Circulation. 2017;135:1832–1847.
- Fujita B, Zimmermann W-H. Engineered heart repair. Clin Pharmacol Ther. 2017;102:197–199.
- Didié M, Christalla P, Rubart M, et al. Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest. 2013;123:1285–1298.
- Zimmermann WH, Melnychenko I, Wasmeier G, et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat Med. 2006;12:452–458.
- Riegler J, Tiburcy M, Ebert A, et al. Human engineered heart muscles engraft and survive long term in a rodent myocardial infarction model. Circ Res. 2015;117:720–730.
- NCT03763136: Treating heart failure with hPSC-CMs (HEAL-CHF) [cited 2019 Dec 08]. Available from: https://clinicaltrials.gov/ct2/show/NCT03763136
- de Wilde S, Coppens DGM, Hoekman J, et al. EU decision-making for marketing authorization of advanced therapy medicinal products: a case study. Drug Discov Today. 2018;23:1328–1333.
- Constitution of the World Health Organization. 1946 [cited 2019 Dec 08]. Available from: www.who.int/governance/eb/who_constitution_en.pdf
- Beauchamp T, Childress J. Principles of biomedical ethics: marking its fortieth anniversary. Am J Bioeth. 2019;19:9–12.